Key Points
- STERIS director Cynthia Feldmann sold 3,098 shares on March 5 at an average price of $237.21 for a total of $734,876.58, cutting her holding by 81.46% to 705 shares (SEC filing).
- STERIS beat/met key results and set upbeat guidance: it posted quarterly EPS of $2.53 (matching estimates) with revenue up 9.2% year-over-year, issued FY2026 EPS guidance of $10.150–$10.300, and carries an analyst consensus of about 9.08 EPS with a $275.20 average price target.
- The company declared a quarterly dividend of $0.63 ($2.52 annualized, ~1.1% yield) payable March 19 to holders of record Feb 17, while shares opened at $230.49 and were trading down roughly 3.4% on the report.
STERIS plc (NYSE:STE - Get Free Report) Director Cynthia Feldmann sold 3,098 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the sale, the director owned 705 shares of the company's stock, valued at $167,233.05. This trade represents a 81.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
STERIS Trading Down 3.4%
Shares of STE stock opened at $230.49 on Friday. The company has a market capitalization of $22.60 billion, a P/E ratio of 32.15 and a beta of 1.05. STERIS plc has a 12-month low of $204.90 and a 12-month high of $269.44. The company has a quick ratio of 1.75, a current ratio of 2.48 and a debt-to-equity ratio of 0.26. The firm has a 50-day moving average price of $254.37 and a 200 day moving average price of $251.51.
STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, hitting the consensus estimate of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. During the same quarter last year, the business earned $2.32 earnings per share. The company's revenue for the quarter was up 9.2% on a year-over-year basis. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Research analysts forecast that STERIS plc will post 9.08 earnings per share for the current fiscal year.
STERIS Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Investors of record on Tuesday, February 17th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, February 17th. STERIS's dividend payout ratio (DPR) is currently 35.15%.
Institutional Investors Weigh In On STERIS
A number of institutional investors and hedge funds have recently modified their holdings of the business. Steigerwald Gordon & Koch Inc. acquired a new position in STERIS in the third quarter valued at approximately $25,000. Board of the Pension Protection Fund acquired a new position in shares of STERIS in the 4th quarter valued at $25,000. Activest Wealth Management boosted its position in shares of STERIS by 423.8% in the 4th quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 89 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new stake in shares of STERIS during the fourth quarter worth $28,000. Finally, Harbor Investment Advisory LLC increased its holdings in STERIS by 115.4% in the fourth quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 60 shares during the last quarter. 94.69% of the stock is owned by institutional investors.
Analysts Set New Price Targets
STE has been the topic of a number of recent analyst reports. Wall Street Zen raised STERIS from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Weiss Ratings reaffirmed a "buy (b)" rating on shares of STERIS in a report on Friday, January 9th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, STERIS presently has an average rating of "Moderate Buy" and a consensus price target of $275.20.
View Our Latest Stock Report on STE
About STERIS
(
Get Free Report)
STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.
Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
